ReviewCirculation. Genomic and precision medicine2025
Artificial Intelligence to Enhance Precision Medicine in Cardio-Oncology: A Scientific Statement From the American Heart Association.
Review in Circulation. Genomic and precision medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Mapping the global landscape of research on immune checkpoint inhibitor-associated cardiotoxicity: A quantitative and visualized bibliometric study (2016-2025).Human vaccines & immunotherapeutics · 2026Article
- Risk-guided cardioprotection in cardio-oncology.Nature cardiovascular research · 2026Review
- Circulating Biomarkers in Cardio-Oncology: Prediction and Prognostication.Current cardiology reports · 2026Review
- The New Cardio-Oncology Frontier in Hematologic Cancers: Cardiovascular Toxicities of CAR-T Cells and Bispecific T-Cell Engagers.Journal of clinical medicine · 2026Review
- Artificial intelligence and the evolution of the electrocardiogram: from cardiovascular diagnostic tool to digital biomarker.European heart journal. Digital health · 2026Review
- Cardiovascular Imaging for the Early Detection of Cardiotoxicity from Emerging Cancer Therapies: Mechanistic Insights Across the Pediatric and Adult Spectrum.Journal of personalized medicine · 2026Review
- Diagnostic and prognostic biomarkers in heart failure and myeloproliferative neoplasms: clinical applications and risk scores - a narrative review.Cardio-oncology (London, England) · 2026Review
- Review
- Wearable Devices and Data Sharing in the US.JAMA network open · 2026Article
- Innovative strategies for early detection of cardiotoxicity: artificial intelligence and multi-modality collaborative models.Journal of thrombosis and thrombolysis · 2026Review
- Artificial Intelligence in Cardiovascular Medicine: A Giant Step in Personalized Medicine?Journal of personalized medicine · 2026Review
- Cardio-Oncology in 2025: From Molecular Mechanisms to Clinical Practice.Balkan medical journal · 2026Article
- Questionnaires on Perceptions of Artificial Intelligence in Health Care Among Health Care Students: Cross-Cultural Translation Into French and Linguistic Validation.JMIR medical education · 2026Article
- Artificial Intelligence and the Expanding Universe of Cardio-Oncology: Beyond Detection Toward Prediction and Prevention of Therapy-Related Cardiotoxicity-A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2026Review
- Research Priorities and Future Directions in Cardio-Oncology.Current treatment options in oncology · 2026Review
- Artificial Intelligence-Enabled Multi-Omics for Predicting Immune Checkpoint Inhibitor Response and Resistance.Journal of multidisciplinary healthcare · 2026Review
- Artificial intelligence in cardio-oncology: decoding mechanisms, predicting toxicity, and personalizing cancer therapy.Frontiers in cardiovascular medicine · 2026Review
- Integrated Cardio-oncology Service.Cardiac failure review · 2026Review
- Cardiovascular Care in Pediatric Cancer Survivors: Updates on Risk, Prevention, and Therapies.Current treatment options in oncology · 2025Review
- Chemotherapy-induced cardiotoxicity in breast cancer: mechanisms, diagnostic advances, and emerging protective strategies.American journal of physiology. Heart and circulatory physiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Artificial intelligence is poised to transform cardio-oncology by enabling personalized care for patients with cancer, who are at a heightened risk of cardiovascular disease due to both the disease and its treatments. The rising prevalence of cancer and the availability of multiple new therapeutic options has resulted in improved survival among patients with cancer and has expanded the scope of cardio-oncology to not only short-term but also long-term cardiovascular risks resulting from both cancer and its treatments. However, there is considerable heterogeneity in cardiovascular risk, driven by the nature of the malignancy as well as each individual's unique characteristics. The use of novel therapies, such as targeted therapies and immune checkpoint inhibitors, across multiple cancer groups has also broadened the populations among which cardiotoxicity has become an important consideration of therapy. Therefore, the ability to understand and personalize cardiovascular risk management in patients with cancer is a key target for artificial intelligence, which can deduce and respond to complex patterns within the data. These advances necessitate an overview of established biomarkers of risk, spanning advanced imaging, diagnostic testing, and multi-omics, the evidence supporting their use, and the proven and proposed role of artificial intelligence in refining this risk to attain greater precision in risk prediction and management in cardio-oncologic care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.